
The Genetics Consultation in OB-GYN :


Hereditary cancers

Célia DeLozier-Blanchet
Division of Medical Genetics,
Geneva University Hospital

It is probable that
all cancers are genetic!

- genetic vs. hereditary
 - constitutional vs. somatic
-

Hereditary vs. sporadic cancers




“Cancer Families”

Family R (Geneva - HNPCC) Branch D

+ = mutation confirmed

- = mutation absent




Features suggestive of an inherited cancer susceptibility

- Several close relatives with a common cancer
- Several close relatives with related cancers
- Two family members with the same rare cancer
- An unusually early age of onset
- Bilateral tumors
- Synchronous or successive tumors
- Tumors in two different systems in the same individual

Age of Onset of Cancer Family R (HNPCC, Geneva)

Number of cases



Principle cancer syndromes and their genes

SYNDROME/ TRANSMISSION

MAIN CANCERS

GENE, CHROMOSOME

Breast / Ovary (AD)

breast, ovary

brca1/ 2 /3 (17q,13q)

Dysplastic Nevus (AD)

melanoma

CMM1 (1p)

Familial Polyposis Coli (AD)

colorectal, duodenal, thyroid

APC (5q)

Familial retinoblastoma (AD)

retinoblastoma

Rba (13q)

Li-Fraumini (AD)

sarcoma, breast, brain,
leukemia, adrenal, etc.

p53 (17p)

Multiple endocrine neoplasia 2 (AD)

thyroid, pheochromocytoma

MEN2a (10q)

Von Hippel-Lindau (AD)

CNS, renal, pancreatic,
pheochromocytoma

VHL (3p)

Classes of “cancer genes”

- Oncogenes
- Tumor suppressor genes
 (“anti-oncogenes”)
- DNA repair genes
- Chromosome instability genes
- Others!

Hereditary cancers :
when to offer genetic testing

Colon Cancer

Lifetime risk of colorectal cancer

(from Houlstan et al. BR MED J 301:366-368, 1990)

- population risk 1/50
- one first-degree relative affected 1/17
- one first & one second degree aff. 1/12
- one relative under 45 affected 1/10
- two first-degree relatives affected 1/6
- three or more first-degree affected 1/2

1100 consecutive colorectal cancer patients

*J. Med Genet 1996
v. 33 981-85*

110 have 1° relative

10 - 15 have APC

5 - 10 have
“convincing” HNPCC

>80: not obvious
which gene to test!

If positive family history, most have mutation in gene on chromosome 5q: **CALL THE GENETICIST!**


If “Amsterdam Criteria” met, most will have mutations that can be defined, genes on 2p, 3p, 7p: **CALL THE GENETICIST!**

What (gene) to test?

Known colon cancer genes



- Familial adenomatosis polyposis 5q
- Hereditary non-polyposis colorectal cancer (HNPCC)
 - Lynch I (colorectal) 2p; 3p
 - Lynch II (colorectal and others) 2q; 18q
- Others!

Gene Testing in Polyposis Coli



Family N (Pakistan/France/England) :

- 3 colorectal malignancies in proband
- MSI-H on rectal tumor /constitutional DNA
- IHC: absence of hMLH1 protein
- mutation hMLH1 : 1528 del/ins (exon 13)



E. coli

MutS

S. cerevisiae

MSH1

(mitochondrial
DNA repair)

MSH2

(nuclear
DNA repair)

MSH3

(minor pathway)

MSH6

H. sapiens

MSH2

(2p)

MSH3

(5q)

GTBP-160

(2p)

Colorectal Cancer Genes and their Mutations

hMLH1 (3p; 19 exons, 100 kB) : up to 60% of HNPCC



hMSH2 (2p; 16 exons, 73 kB) : up to 30% of HNPCC




- Numerous distinct mutations (splice-site, missense and nonsense)
- For hMLH1, clustering in exons 15 - 16?
- Probable ethnic variations (founder effect?)

Why use microsatellites (MSIs) to detect DNA repair defects ?

- **MSIs are sensitive indicators of DNA instability**
- **They are the most hyper-mutable regions in the coding regions of human DNA (10^3 - 10^6) per gamete)**
 - **unequal crossing-over**
 - **“slippage” of DNA polymerase during replication**
 - **Not recognized by DNA repair mechanisms?**

What does microsatellite instability look like ?

When separated by size, tumor DNA (T) and constitutional DNA (C) show different patterns of bands in the same patient



Electrophoresis of PCR amplification products

Microsatellites : stability vs instability ?

Extra bands in tumor vs. constitutional DNA

- 0 / 5 MSIs instable : **MSS** (microsatellite stability)
- 1 / 5 MSIs instable : **MSI-L** (weak instability)
- 2 or more / 5 instable : **MSI-H** (high instability)

69 cases tested in 2000

- 12 MSI-H
- 0 MSI-L

Analysis of MSI in patient's DNA

biopsy tumor
tissue

blood sample or biopsy
"healthy" tissue



Extract DNA



PCR amplification of MSIs



Separate products by size;
migration on electrophoretic gel



Radioactive allele revelation



Compare **Tumoral** and **constitutive** DNA

Conclusion: MSI STABILITY or INSTABILITY

Conditions with potential prophylactic treatment
(from Mueller and Young, "Emery's Elements of Medical Genetics, 1995, p 179)

Disorder

● *Accepted treatment*

FAP (colon polyposis)

Ovarian cancer families

Breast cancer families

MEN2

● *Under evaluation*

FAP (colon polyposis)

Breast cancer families

Treatment

Total colectomy

Oophorectomy

Bilateral mastectomy

Total thyroidectomy

Non-digestible starches;

Sulindac

Tamoxifen

Advantages of cancer gene testing

- Knowing
- Improved diagnosis and prognosis?
- Half of at-risk individuals will not have the gene!
- Advances in knowledge of genotype/phenotype correlations

Why use microsatellites (MSIs) to detect DNA repair defects ?

- **MSIs are sensitive indicators of DNA instability**
- **They are the most hyper-mutable regions in the coding regions of human DNA (10^3 - 10^6) per gamete)**
 - **unequal crossing-over**
 - **“slippage” of DNA polymerase during replication**
 - **not recognized by DNA repair mechanisms?**

How is MSI instability detected ?

consensus of 5 microsatellites (workshop 1997)
BAT25, BAT26, D2S123, D5S346, D17S250,

Locus/Name	chr	Primer name	Primer sequence
BAT25 <i>4q12-4q12</i>	4	BAT-25.1	TCGCCTCCAAGAATGTAAGT
		BAT-25.2	TCTGCATTTTAACTATGGCTC
BAT26 <i>2p16-2p16</i>	2	BAT-26.1	TGACTACTTTTGACTTCAGCC
		BAT-26.2	AACCATTCAACATTTTAAACCC
D5S346 <i>5q21-q22</i>	5	LNS-CAI	ACTCACTCTAGTGATAAATCGGG
		LNS-CAII	AGCAGATAAGACAGTATTACTAGTT
D2S123 <i>2p16</i>	2	AFM093xh3a	AAACAGGATGCCTGCCTTTA
		AFM093xh3m	GGACTTTCCACCTATGGGAC
D17S250 <i>17q11.2-q12</i>	17	Mfd15CA	GGAAGAATCAAATAGACAAT
		Mfd15GT	GCTGGCCATATATATATTTAAACC

Analysis of MSI in patient's DNA

biopsy tumor
tissue

blood sample or biopsy
"healthy" tissue



Extract DNA



PCR amplification of MSIs



Separate products by size;
migration on electrophoretic gel



Radioactive allele revelation



Compare **Tumoral** and **constitutive** DNA


Conclusion: MSI STABILITY or INSTABILITY

Microsatellites : stability vs instability ?

Extra bands in tumor vs. constitutional DNA

- 0 / 5 MSIs instable : **MSS** (microsatellite stability)
- 1 / 5 MSIs instable : **MSI-L** (weak instability)
- 2 or more / 5 instable : **MSI-H** (high instability)

Genetic testing in HNPCC



Why test?

Other cancers in HNPCC carriers?

- **Endometrial cancer risk:** 40-60% for women (depending on the gene, is greater than the colon cancer risk!) Yearly US recommended.
- Somewhat increased risk of urinary tract, pancreas, ovary, prostate, breast??

Genotype - phenotype correlations

- The tumor spectrum (types and frequencies) is different according to the gene implicated!
 - ***hMLH1*** : paucity of extra-colonic tumors (but endometrial cancer in females; breast?)
 - ***hMLS2*** : more cancers of renal pelvis, ureter, stomach, ovaries
 - ***hMSH6*** : endometrial and ovarian outnumber CR

Amsterdam positive (but mutation-negative) families: more breast and prostate than in above groups...

HNPCC : how MSI / mutation identification affects treatment

- for the affected individual
- modifies surgical options
- may modify treatment protocols (radio- and chemotherapy)
- is NOT a negative factor for prognosis
- For the individual and the family
- allows pre-symptomatic testing
- increases/modifies clinical and paraclinical follow-up (endometrium in women)
- access to treatment trials (CAPP2)

Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection

JOSEF RÜSCHOFF*†‡§, SABINE WALLINGER*†, WOLFGANG DIETMAIER*, TINA BOCKER¶, GERO BROCKHOFF*, FERDINAND HOFSTÄDTER*, AND RICHARD FISHEL‡¶

*Institute of Pathology, University of Regensburg, D-93042 Regensburg, Germany; and ¶Genetics and Molecular Biology Program and Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, Philadelphia, PA 19107

Edited by Alfred G. Knudson Jr., Institute for Cancer Research, Philadelphia, PA, and approved July 31, 1998 (received for review May 7, 1998)

PNAS 95:11301-11306, 1998

Hereditary cancer: concerns that impact genetic counseling

- concerns about insurability
- family pressure for testing and seeking results
- unresolved grief
- family solidarity
- survivor guilt
- barriers to screening (financial, psychological)
- prophylactic surgery
- patient/physician/counselor communication

from American Cancer Society second national conference on Cancer Genetics, Lynch et al., CANCER 86 (suppl):2457-2463, Dec.1999

ASHG /ACMG Report

Points to consider : Ethical, legal and psychosocial implications of genetic testing in children and adolescents (Am J Hum Genet 57:1233-1241, 1995)

Counseling and communication with child and family should include:

- assessment of the significance of the potential benefits and harms of the test
- determination of the decision-making capacity of the child
- advocacy on behalf of the interests of the child

Breast cancer genes

- 17q (BRCA1)
- 13q (BRCA2)
- 11p ?
- AT gene?